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ABSTRACT 
Objective: The objective of this study to investigate the effect of simvastatin on kidney fibrosis in mice with a 5/6 subtotal nephrectomy. 
Methods: Thirty adults (3 mo old) male Swiss mice were submitted to a 5/6 subtotal nephrectomy and studied after 14 d. Animals were divided into five 
groups: 5/6 subtotal nephrectomy (SN, n=6), sham operation (SH, n=6), simvastatin 5.2 mg/kg body weight (SIM-1, n=6), simvastatin 10.4 mg/kg body 
weight (SIM-2, n=6), and simvastatin 20.8 mg/kg body weight (SIM-3, n=6) groups. At sacrifice, kidneys were harvested for morphology (glomerulosclerosis 
(GS), tubular injury and interstitial fibrosis), immunostaining (α-smooth muscle actin (α-SMA)) and platelet-derived growth factor receptor beta (PDGF-Rβ) 
and reverse transcriptase-polymerase chain reaction (RT-PCR) (MCP-1, ICAM-1, nephrin, and podocin) analysis.  
Results: Glomerulosclerosis, tubular injury and interstitial fibrosis in the simvastatin group was significantly lower than SN group (p<0.05). 
Simvastatin significantly reduced α-SMA expression (3.61±1.06 vs 7.91±1.26, p<0.05, SIM-1 vs SN; 2.86±0.61 vs 7.91±1.26, p<0.05, SIM-2 vs SN; 
1.71±0.50 vs 7.91±1.26, p<0.05, SIM-3 vs SN), MCP-1 was markedly expressed in the 5/6 subtotal nephrectomy kidneys and was reduced with 
simvastatin (1.4±0.64 vs 0.57±0.23, p<0.05, SN vs SIM-1; 1.4±0.64 vs 0.6±0.26, p<0.05, SN vs SIM-2; 1.4±0.64 vs 0.52±0.21, SN vs SIM-3, p<0.05). 
Simvastatin did not increase nephrin expression, but it increased podocin expression significantly in the SIM-3 group. 
Conclusion: Simvastatin significantly attenuated GS, tubular injury and interstitial fibrosis through the downregulation of myofibroblast expansion 
and inflammatory mediators in mice with a 5/6 subtotal nephrectomy. 
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Chronic kidney disease (CKD) is a global health problem. The global 
increase in incidence and prevalence of CKD is associated with 
increased morbidity and mortality risks as well as a direct increase 
in the financial burden [1]. There are various factors which may lead 
to CKD such as diabetes mellitus, hypertension, infection 
(glomerulonephritis, chronic pyelonephritis), and urinary tract 
obstruction [2, 3]. These diseases have the ability to cause an 
increase in intraglomerular pressure, barrier filtration permeability, 
endothelial cell dysfunction, mesangial, podocyte, and tubular cell 
activation, extracellular matrix synthesis, proteinuria/albuminuria 
and decrease glomerular filtration rate (GFR)[2].  
Pharmacological therapy for CKD is primarily aims to address the 
underlying causes and prevent the progression of the disease. Renin 
angiotensin aldosteron system inhibitor (RAASI) has proven to be the 
most effective therapy in reducing proteinuria and slowing the 
progression of CKD [2]. Meanwhile, statins are the pharmacologic 
intervention of choice for dyslipidemia, which is the greatest risk factor 
for cardiovascular (CV) events and the progression of kidney disease [4]. 
Preclinical research in the last few decades has reported that statins 
have pleotropic effects, giving it the ability to inhibit the mevalonate 
pathway, especially the inhibition of isoprenoid metabolism [5, 6]. 
One of which are for the prevention of renal fibrosis [1]. Fibrosis 
may be inhibited through different mechanisms, including: 
inhibition of Rho family proteins (RhoA and Rac-1) and reversal of 
podocyte damage [3, 7], inhibition of the HOXA13-USAG-1 pathway 
[1], inhibition of the angiotensin II/Smad pathway [8], inhibition of 
ACE expression and aldosterone production [9], inhibition of NF-κB 
activation, IL-1β, TGF-β1 and oxidative stress expression [10, 11], as 
well as inhibition of the MAPK signaling pathway [6]. 
However, the effect of statins in preventing CKD progression is still 
unclear and controversial. Statins have shown to have preventive 
effects on cardiovascular disorders, but no effect on the kidneys 
[12]. The advantages of statin use in clinical practice is also unclear, 
although it is likely to have an effect in preventing proteinuria 
depending on the dose and duration of use [13, 14]. Therefore, we 
investigated the effect of simvastatin on kidney fibrosis model in 
mice with a 5/6 subtotal nephrectomy. 
MATERIALS AND METHODS 
Thirty adult (3 mo old) male Swiss mice, weighing 30-40 g, obtained 
from Animal Care Unit, Universitas Gadjah Mada (Yogyakarta, 
Indonesia), were used in this study. The animals were randomized 
and maintained under standard laboratory conditions (at 22+2 °C; 
50±5 % humidity; 12/12 h light/dark cycle) with accessed libitum to 
an animal diet and tap water [15]. All experimental procedures were 
conducted according to the Medical and Health Research Ethics 
committee Faculty of Medicine, Universitas Gadjah Mada number 
Ref: KE/FK/234/EC. 
5/6 Subtotal nephrectomy procedure and administration of 
simvastatin 
The animals were divided into five groups: the nephrectomy (SN, 
n=6), sham operation (SH, n=6), simvastatin 5.2 mg/kg body weight 
(SIM-1, n=6), simvastatin 10.4 mg/kg body weight (SIM-2, n=6), and 
simvastatin 20.8 mg/kg body weight (SIM-3, n=6) groups. A sham 
operation procedure was performed on the SH group and a 5/6 
subtotal nephrectomy procedure was performed on the SN and 
simvastatin (SIM-1, SIM-2, SIM-3) groups and they were terminated 
after 14 d. Simvastatin (Sigma-Aldrich, Science Park Road, 
Singapore) was dissolved in a 1 % solution of carboxymethyl 
cellulose administered once a day by oral gavage (Sigma-Aldrich, St 
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Louis, MA, USA). The 5/6 subtotal nephrectomy procedure was 
performed after anaesthetized with a 0,1 ml/10g body weight i. p. 
injection of sodium pentobarbital. In this model, we performed a 
unilateral nephrectomy on the right kidney and 2/3 of the remaining 
kidney was ablated by a polar excision 1 d after the uninephrectomy. 
Biochemistry analysis 
Serum creatinine was measured with a kinetic test without 
deproteinization according to the Jaffe method (DiaSys, Holzheim 
Germany), proteinuria was measured with a dipstick (YD 
Diagnostics, Seoul, Korea), total serum cholesterol was measured 
with the enzymatic photomeric test (DiaSys, Holzheim, Germany) 
and serum triglyceride was measured with the colorimetric 
enzymatic test using GPO (DiaSys, Holzheim, Germany). 
Morphology 
At the end of the study, the mice were anaesthetized with a 0.1 ml/g 
body weight i. p. injection of sodium pentobarbital. The material was 
then embedded in paraffin for assessment of GS, tubular injury and 
for immunohistochemical studies. Paraffin-embedded renal tissue 
was dewaxed using standard sequential techniques, and 4 µm-thick 
sections were stained with periodic acid-schiff (PAS). The 
morphological measurement was performed blindly by a double-
observer. 
The extent of GS was graded from 0 to 4 with a semi quantitative score 
based on the extent of glomerular damage (sclerosis), capillary loops 
and synechia between glomerular capillaries and the Bowman’s 
capsule (0, normal; 1, mesangial expansion/sclerosis involving<25 % 
of the tuft; 2, moderate GS (25 to 50 %); 3, severe GS (50 to 75 %); and 
4, diffuse GS involving>75 % of the glomerular tuft). For each kidney, 
the sum of the results for 20 glomeruli was defined as the 
glomerulosclerosis index (GSI). The GSI of each mouse was calculated 
as a mean value of all the glomerular scores obtained [16]. 
The tubular injury scores were determined through a 
semiquantitative scoring system. Ten fields were examined for each 
kidney, and the lesions were graded from 0 to 3 (0, no change; 1, 
changes affecting<25 % of the section; 2, changes affecting 25 to 50 
% of the section; and 3, changes affecting 50 to 100 % of the 
section), according to the area with tubulointerstitial lesions 
(tubular atrophy, tubular dilatation, loss of brush border, 
intraluminal casts, interstitial inflammation and fibrosis). The score 
index of each mouse was expressed as a mean value of all scores 
obtained. 
Immunohistochemical (IHC) staining 
The expression of α-SMA, a marker of myofibroblast expansion, and 
PDGF-Rβ, a marker of fibroblast were identified through IHC 
staining using standard techniques. Sections 4 µm-thick were 
obtained from paraffin-embedded tissue and subjected to 15 min 
microwave heating in citrate buffer for antigen retrieval. Then, 
slides were incubated with 1:500 monoclonal anti-α-SMA (Sigma-
Aldrich, St Louis, MO, USA) and 1:200 anti-PDGF-Rβ (Abcam, 
Cambridge, USA) overnight in a humidified chamber at 4 °C. The 
sections were then incubated with appropriate species-specific 
secondary antibodies (Biocare Medical, Concord, CA, USA) for 1 h at 
room temperature. The avidin-biotinylated horseradish peroxidase 
technique (Biocare Medical, Concord, CA, USA) was used to complete 
the detection of antigens. The PDGF-Rβ expression was quantified 
by counting positive cells, and α-SMA expression was expressed as 
fraction area percentage (%) using Image J software version 1.40. 
For each section at least 10 consecutive 400x magnification fields of 
the cortex were examined. 
RNA extraction, cDNA synthesis, RT-PCR 
Total RNA was extracted using RNA iso plus (Takara, Otsu, Japan) 
based on the protocol from the manufacturer, and the RNA 
concentration was quantified by spectrometry. We used 1000 ng 
RNA for the cDNA synthesis. cDNA was synthesized using Rever Tra 
Ace (Toyobo, Osaka, Japan) and random primer (Takara, Otsu, 
Japan), with the following PCR conditions: 30 °C for 10 min 
(denaturation), 42 °C for 60 min (annealing) and 99 °C for 5 min 
(extension).  
RT-PCR was carried out to amplify the following specific cDNAs. The 
primers that were used as: nephrin 5’-CCCCTCTATGATGAAGTA-
CAAATGGA-3’ (forward) and 5’-GTACGATTTCCTCAGGTCTTCT-3’ 
(reverse); podocin 5’-GAAAGGAAGAGCATTGCCCAAG-3’(forward) and 
5’-TGTGGACAGCGACTGAAGAGTGTG-3’(reverse); ICAM-1 5’-AAACGGG-
AGATGAATGGTACCTAC-3’(forward) and 5’-TGCACGTCCCTGGTGA-
TACTC-3’(reverse); MCP-1 5’ACTGAAGCTCGTACTCTC-3’(forward) and 
5’-CTTGGGTTGTGGAGTGAG-3’(reverse); GAPDH 5’-TCACCATCTTCCA-
GGAGCG-3’(forward) and 5’-CTGCTTCACCACCTTCTTGA-3’ (reverse).  
RT-PCR was performed by mixing 2 µl of cDNA, 12.5 µl of Tag 
master mix (Bioron, Ludwigshafen, Germany), 0.6 µl of forward 
primer, 0.6 µl of reverse primer and 9.3 µl of PCR water. The 
cDNAs were amplified according to the following conditions: 94 °C 
for 2 s (initial denaturation), 94 °C for 10 s (denaturation), 60 °C 
for 20 s (the annealing temperature varied for each pair of 
primers), 72 °C for 1 min (extension) and 72 °C for 10 min (last 
extension). The number of cycles was redetermined for each pair 
of primers in order to avoid the PCR plateau phase. The PCR 
products were analyzed in 2 % agarose gel along with a 100 bp 
DNA ladder (Bioron, Ludwigshafen, Germany). The expression of 
the genes was quantified with a densitometry analysis using the 
ImageJ software version 1.40. The GAPDH expression was used to 
normalized the expression. 
Statistical analysis 
The results are expressed as mean±SEM. multiple comparisons 
among the groups were done by one-way analysis of variance 
(ANOVA) and followed by the post hoc Tukey’s test. The level of 
statistical significance was p<0.05. 
RESULTS 
There was a significant difference in body weight between the SH 
group (36.51±1.11 g) and SN group (30.51±3.24 g) at the end of the 
study. The serum creatinine levels of the SN group (1.89±0.32 
mg/dl) were significantly higher than the SH group (0.43±0.04 
mg/dl) 2 w after the operation. There was an increase in plasma 
creatinine levels and proteinuria in the mice with 5/6 subtotal 
nephrectomy. However, differences among the level of total 
cholesterol and triglyceride were not found among the five groups 
(fig.1). Treatment with simvastatin decreased plasma creatinine 
levels and attenuated proteinuria, but did not affect the lipid 
profiles. The following data indicates the pleiotropic effects of 
statins in mice with nephrectomies.  
Glomerulosclerosis, tubular injury score and interstitial 
fibrosis 
The mice kidneys with 5/6 subtotal nephrectomy developed 
conspicuous GS and tubular injury consisting of tubular dilatation 
and atrophy, intraluminal casts, interstitial inflammation and a 
marked interstitial fibrosis as shown by quantification of GSI and 
tubular injury score in SN group compared to SH group. 
Glomerulosclerosis index and tubular injury score on PAS staining 
showed that simvastatin significantly attenuated GS (2.39±0.34 vs 
3.95±0.06, p<0.05, SIM-1 vs SN; 2.23±0.49 vs 3.95±0.06, p<0.05, 
SIM-2 vs SN; 1.98±0.23 vs 3.95±0.06, p<0.05, SIM-3 vs SN) and 
tubular injury (2.19±0.32 vs 3.97±0.04, p<0.05, SIM-1 vs SN; 
1.78±0.36 vs 3.97±0.04, p<0.05, SIM-2 vs SN; 1.63±0.67 vs 
3.97±0.04, p<0.05, SIM-3 vs SN) (fig. 2). 
Myofibroblast and fibroblast expansion 
In the kidneys of the SH group, α-SMA was expressed in the smooth 
muscle cells of renal arterioles, whereas 5/6 subtotal nephrectomy 
caused an increase in the expression of α-SMA positive cells in the 
interstitium compartment known as myofibroblast. Meanwhile, 
simvastatin treatment significantly reduced myofibroblast fraction 
area (3.61±1.06 vs 7.91±1.26, p<0.05, SIM-1 vs SN; 2.86±0.61 vs 
7.91±1.26, p<0.05, SIM-2 vs SN; 1.71±0.50 vs 7.91±1.26, p<0.05, 
SIM-3 vs SN) (fig.3). 
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Fig. 1: Effect of simvastatin on creatinine serum, proteinuria, total cholesterol, and triglyceride. □ = p<0.05 vs SN, Δ = p<0.05 vs SH, SH 
(sham operation), SN (5/6 subtotal nephrectomy), SIM (5/6 subtotal nephrectomy+simvastatin) 
 
 
Fig. 2: (A) Renal histological changes evaluated with PAS staining and interstitial fibrosis evaluated with Picrosirus Red. (B) The bar 
graph summarizes the number of GS, tubular injury score and interstitial fibrosis. □ = p<0.05 vs SN, Δ = p<0.05 vs SH, SH (sham operation), 
SN (5/6 subtotal nephrectomy), SIM (5/6 subtotal nephrectomy+simvastatin) 
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Fig. 3: (A) Immuno-histochemical analysis of α-SMA and PDGF-Rβ. (B) Bar graph summarizes a number of α-SMA and PDGF-Rβ. □ = p<0.05 
vs SN, Δ = p<0.05 vs SH, SH (sham operatian), SN (5/6 subtotal nephrectomy), SIM (5/6 subtotal nephrectomy+simvastatin) 
 
 
Fig. 4: (A) Representative gels of MCP-1, ICAM-1, nephrin and podocin expressions. (B) Densitometric analysis of MCP-1, ICAM-1, nephrin 
and podocin protein expressions. □ = p<0.05 vs SN, Δ = p<0.05 vs SH, SH (sham operatian), SN (5/6 subtotal nephrectomy), SIM (5/6 
subtotal nephrectomy+simvastatin) 
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MCP-1, ICAM-1, nephrin and podocine expression 
In order to investigate the status of podocyte integrity and 
inflammatory markers in mice with 5/6 subtotal nephrectomy, we 
studied the expressions of nephrin, podocin, MCP-1, and ICAM-1. In 
this study, the MCP-1 and ICAM-1 expressions of the SN group were 
significantly higher than the SH group. Treatment with simvastatin 
reduced this expression significantly. The nephrin expression in the 
SN group was lower than the SH group, though this was not 
statistically significant. Treatment with simvastatin was able to 
improve this expression, but this was also not statistically 
significant. Amelioration of podocyte integrity was shown by higher 
expression of podocin in simvastatin treatment groups compare to 
SN group. Contrast to the nephrin expressions, podocin expression 
in the SN group was significantly lower than the SH group 
(0.32±0.12 vs 0.53±0.09, p<0.05, SN vs SH). Simvastatin treatment in 
the SIM-3 group also appeared to attenuate podocin expression 
significantly than in the SN group (0.52±0.1 vs 0.32±0.12, p<0.05, 
SIM-3 vs SN) (fig. 4). 
DISCUSSION 
Two weeks of 5/6 subtotal nephrectomy was associated with loss of 
functional nephrons which induced glomerular hyperfiltration, 
compensatory renal hypertrophy, systemic hypertension, and 
functional and morphological damage of the remaining kidney [15-
17]. As expected, in this study the 5/6 subtotal nephrectomy mice 
showed impaired renal function and proteinuria, accompanied by 
severe GS, tubular injury and interstitial fibrosis, as well as 
myofibroblast expansion. 
Renal function impairment is characterized by increased levels of 
serum creatinine and proteinuria in the SN group compared with the 
SH group. Statins have been reported to reduced the levels of serum 
creatinine [18-20], C-reactive protein, BUN, eGFR and proteinuria 
[14, 18, 20, 21], which is consistent with the results of this study. 
The duration and dose of the therapy appears to have affected these 
renoprotective effects [13, 14]. However, a study on an NO deficiency 
model reported no difference in the levels of serum creatinine after 
administration of statins among the groups [22]. Proteinuria may 
occur as a result of glomerular filtration and tubular reabsorption 
dysfunction [20]. Statins may moderately reduce pathologic excretion 
of urine albumin and proteinuria within a period of 6 mo after 
initiation of the therapy and may reduce the rate of kidney disease 
progression when combined with RAASI [22, 23]. 
Dyslipidemia is a major problem in CKD, which lead to higher risk of 
CV disease and renal function deterioration [4, 25]. The results of 
previous studies suggest that statins have pleiotropic effects in a 
cholesterol-independent reduction manner [19, 22, 26-30], though 
the mechanisms have not been sufficiently revealed yet. The total 
cholesterol and triglyceride levels between treatment groups in this 
study showed no significant differences (p<0.05). These results 
indicate that simvastatin can improve kidney function, but have no 
effect on cholesterol levels and triglyceride. However, other studies 
have reported that administration of atorvastatin 100 mg/kg/d 
significantly lowers total cholesterol, LDL, VLDL, and improves HDL 
[30], reduces TC concentrations by 13 % in patients with CKD, have 
protective effects on CV events and mortality in patients with or 
without established CV diseases [4]. The decrease in LDL levels was 
parallel to the increasing doses of statins and significantly different 
between the statin types used, however this had no significant 
implications on clinical practice [31]. 
In this study, treatment with simvastatin reduced the GS, tubular 
injury score and interstitial fibrosis. The results of the semi 
quantitative analysis on GS and tubular injury score in the 
simvastatin groups (SIM-1, SIM-2, SIM-3) were significantly lower 
than SN group (p<0.05). Glomerulosclerosis is associated with 
extracellular matrix deposition, abnormal mesangial cell expansion 
and increased kidney inflammation [11]. Simvastatin prevents GS 
through anti-inflammatory effects such as decreased pro-
inflammatory cytokines (IL-6, IL-1β, TGF-β and TNF-α) [10, 22], 
decreased NF-κB expression [10], and increased hepatocyte growth 
factor, BMP-7 and Smad 7 expressions which improves renal blood 
flow [28]. Simvastatin is also known to improve 24 h urine albumin 
excretion ratio and increase nephrin expression [7]. In this study we 
found that there was no significant difference in nephrin expression 
between the groups (p>0.05). However, in the SIM-3 group, 
treatment with simvastatin appeared to reduce podocin expression 
significantly. 
In contrast to the glomerular lesion, the tubular injury was 
predominantly caused by an increase in total interstitial cell volume 
(which may represent increased cell size and/or number), preceding 
the accumulation of interstitial collagen. These interstitial cells include 
myofibroblast cells, which have pivotal roles as a major source of 
collagen synthesis in interstitial fibrosis and increased expression of α-
SMA [32, 33]. Previous studies have reported that simvastatin can 
slow fibrosis by decreasing CTGF and α-SMA expressions in a diabetic 
nephropathy model [34], preventing the activation and trans 
differentiation of tubular cells (decreasing type 1 collagen, fibronectin, 
α-SMA, and vimentin expressions) [25], as well as reducing MCP-1 and 
p21 expresions [27]. In this study, we also found that simvastatin 
reduced MCP-1 expression at 3 different doses and reduced ICAM-1 at 
the highest dose (20.8 mg/kg body weight). 
Alpha-SMA is an intermediate filament used as a marker for 
myofibroblast. In normal mice kidneys, α-SMA expression is limited 
to the vascular smooth muscle artery [35, 36]. Based on data from 
this study, we found that treatment with simvastatin reduced the 
expansion of myofibroblast at each of the given doses. Decreased α-
SMA was also reported through treatment with 2 mg/kg simvastatin 
on a UUO model [25]. These results are similar with other in vitro 
studies in which simvastatin inhibits the production of α-SMA in 
keloid fibroblasts [37], blocks calcific nodule formation in valvular 
interstitial cells by inhibiting α-SMA expression [38]. Here we 
revealed simvastatin effect on attenuating kidney injury 
independent to its lowering lipid effect. lipid lowering-independent 
effect of simvastatin is also known into decreasing human atrial 
myofibroblast proliferation regardless of cholesterol decrease via 
inhibition of RhoA [39]. Furthermore, simvastatin-induced cardiac 
fibroblast cytoskleton, adhesion, migration and viability [40]. 
Meanwhile, other study also revealed nephrotoxicity effect of high 
dose atorvastatin independent to oxidative stress but may be due to 
rhabdomyolisis [41]. For future studies, it is needed to consider the 
dose-dependent effect of statin in renal patology. 
CONCLUSION 
In conclusion, in this model, simvastatin significantly attenuated 
kidney fibrosis. These effects can be seen through the decrease in GS, 
tubular injury and interstitial fibrosis which appear to result from 
the reduction of myofibroblast expansion and inflammatory 
mediators. Beyond its effect, statins might prove to be an effective 
adjunctive treatment in renal disease. 
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